REFERENCES
1. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Belgium: International Diabetes Federation, 2021.
2. Standards of specialized diabetes care. Edited by I.I. Dedov, M.V. Shestakova, A. Yu. Mayorov. 10th edition (revised). Moscow; 2021. DOI: https://doi.org/10.14341/DM12802
3. Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov MA Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal Diabetes Register data of 01.01.2021. Sakharni diabet [Diabetes Mellitus]. 2021; 24 (3): 204-21. DOI: https://doi.org/10.14341/DM12759 (in Russian)
4. Li S., Wang J., Zhang B., Li X., Liu Y. Diabetes mellitus and cause-specific mortality: a population-based study. Diabetes Metab J. 2019; 43 (3): 319-41. DOI: https://doi.org/10.4093/dmj.2018.0060
5. Hiatt W.R., Kaul S., Smith RJ. The cardiovascular safety of diabetes drugs insights from the rosiglitazone experience. N Engl J Med. 2013; 369 (14): 1285-7. DOI: http://dx.doi.org/10.1056/NEJMp1309610; PMID: 23992603.
6. Su G., Mi S., Tao H., et al. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2011; 10: 19. DOI: https://doi.org/10.1186/1475-2840-10-19
7. DeVries J.H., Bailey T.S., Bhargava A., et al. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treatedpatients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials. Diabetes Obes Metab. 2019; 21: 622-30. DOI: https://doi.org/10.1111/dom.13565
8. Fernandez C.J., Radhakrishnan C. Efficacy and cardiovascular safety of insulins. Curr Drug Saf. 2021; 16 (2): 217-32. DOI: https://doi.org/10.2174/1574886315999201105153458; PMID: 33153425.
9. Khunti K., Davies M., Majeed A., Thorsted B.L., et al. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care. 2015; 38 (2): 316-22. DOI: http://dx.doi.org/10.2337/dc14-0920; PMID: 25492401.
10. Zinman B., Marso S.P., Poulter N.R., et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2018; 61 (1): 48-57. DOI: https://doi.org/10.1007/s00125-017-4423-z; PMID: 28913575.
11. Pieber T.R., Marso S.P., McGuire D.K., et al. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabeto-logia. 2018; 61 (1): 58-65. DOI: https://doi.org/10.1007/s00125-017-4422-0
12. Ceriello A. Targeting one-hour postmeal glucose: is it time for a paradigm switch in diabetes management? Diabetes Technol Ther. 2017; 19: 493-7. DOI: https://doi.org/10.1089/dia.2017.0135; PMID: 28665142.
13. Lu J., Wang C., Shen Y., Chen L., et al. Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study. Diabetes Care. 2021; 44 (2): 549-555. DOI: https://doi.org/10.2337/dc20-1862; PMID: 33097560.
14. Davies M.J., D'Alessio D.A., Fradkin J., et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabeto-logia. 2018; 61: 2461-98. DOI: https://doi.org/10.1007/s00125-018-4729-5
15. Goldenberg R.M., Aroda V.R., Billings L.K., et al. Effect of insulin degludec versus insulin glargine U 100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia. Diabetes Obes Metab. 2021; 23 (11): 2572-581. DOI: https://doi.org/10.1111/dom.14504
16. Billion L., Charleer S., Verbraeken L., et al. Glucose control using fastacting insulin aspart in a real-world setting: A 1-year, two-centre study in people with type 1 diabetes using continuous glucose monitoring. Diabetes Obes Metab. 2021; 23 (12): 2716-27. DOI: https://doi.org/10.1111/dom.14527
17. Franek E., Ekelund M., Thorisdottir O., Jang H., et al. 1034-P: Efficacy and safety of fast-acting insulin aspart according to baseline HbA1c in adults with type 2 diabetes treated with a basal-bolus regimen. Diabetes. 2020; 69 (Suppl. 1): 1034-P. DOI: https://doi.org/10.2337/db20-1034-P
18. Moon S., Chung H.-S., Kim Y.-J., Yu J.-M., et al. Efficacy and safety of insulin degludec/ insulin aspart compared with a conventional premixed insulin or basal insulin: a meta-analysis. Metabolites. 2021; 11 (9): 639. DOI: https://doi.org/10.3390/metabo11090639
19. Shestakova M.V., Surkova E.V., Vachugova A.A., Ipatko I.A., et al. The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists. Sakharni diabet [Diabetes Mellitus]. 2021; 24 (2): 175-84. DOI: https://doi.org/10.14341/DM12747 (in Russian)
20. Cosentino F., Grant P., Aboyans V., Bailey C., et al. ESC Scientific Document Group, 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020; 41 (2): 255-323. DOI: https://doi.org/10.1093/eur-heartj/ehz486
21. Norhammar A., Ake T., Goran N., Anders H., et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002; 359 (9324): 2140-4. DOI: https://doi.org/10.1016/S0140-6736(02)09089-X